Kodiak Sciences Inc
KODHealthcare|Biotechnology|USA
$41.28
+1.23 (+3.07%)
Tangible Book
$1.80
About
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
Stock Price
+819.4%(1Y)
Pipeline Summary
11 total trials1
Phase 1
1
Phase 2
10
Phase 3
0
Phase 4
Terminated: 5Completed: 3Recruiting: 2Active: 1
Active Trials (3)
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE
NCT06996080Macular Edema Secondary to Inflammation
Phase 3Recruiting
Enrollment: 300 participants
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
NCT06556368Wet Age-related Macular Degeneration
Phase 3Active
Enrollment: 675 participants
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK
NCT06990399Macular Edema Secondary to Inflammation
Phase 3Recruiting
Enrollment: 600 participants
BioScore
4/10
Cautious
Ownership
Recent Insider Trades
BORGESON JOHN A.SELL
2026-06-0430,000 shares @ $34.1
BORGESON JOHN A.SELL
2026-04-0230,000 shares @ $39.92
BAKER BROS. ADVISORS LPBUY
2025-12-182,608,696 shares @ $23
BORGESON JOHN A.SELL
2025-06-17723 shares @ $3.65
BORGESON JOHN A.SELL
2024-06-172,874 shares @ $2.75
Data last updated: Jul 13, 2026, 12:42 PM